Literature DB >> 8095452

Polycystic ovarian disease as a neuroendocrine disorder of the female reproductive axis.

J E Hall1.   

Abstract

Despite many years of investigation, the benign syndrome(s) of hyperandrogenic amenorrhea, commonly known as PCOD, remains an enigma. Although hyperinsulinemia and hyperandrogenemia from any cause may produce many of the signs and symptoms common to PCOD secondarily, there exists a subset of patients in whom the major abnormality is neuroendocrine. These patients have a gonadotropin profile characterized by an elevated amplitude of LH pulsations in association with normal to low levels of FSH and a fast frequency of pulsatile LH secretion. A major question still remaining is whether the neuroendocrine abnormality is primary or secondary to abnormal ovarian feedback by androgens, or more likely, estrogens. Some evidence suggests that the pattern of secretion of LH and FSH from the pituitary may be owing solely to an increased frequency of GnRH stimulation, but there is little evidence of a specific primary abnormality of neurotransmitters. Subsequent studies in which the various subgroups of PCOD are carefully delineated will be required to clarify these relationships and in so doing provide patients with optimal therapeutic choices.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095452

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  3 in total

1.  Progesterone treatment inhibits and dihydrotestosterone (DHT) treatment potentiates voltage-gated calcium currents in gonadotropin-releasing hormone (GnRH) neurons.

Authors:  Jianli Sun; Suzanne M Moenter
Journal:  Endocrinology       Date:  2010-08-25       Impact factor: 4.736

Review 2.  Comparison of dietary intake and physical activity between women with and without polycystic ovary syndrome: a review.

Authors:  Annie W Lin; Marla E Lujan
Journal:  Adv Nutr       Date:  2014-09       Impact factor: 8.701

Review 3.  Polycystic ovary syndrome and epilepsy: a review of the evidence.

Authors:  Roberta Meo; Leonilda Bilo
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.